Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. was founded in 2002, with its headquarters located in Irving, Texas. It is a clinical-stage biopharmaceutical company that develops novel therapies for patients with serious or life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation regulation.Reata Pharmaceutical’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and address inflammation.